Prof. Jianghua Ou 欧江华
Chief Physician, Professor
Department of Breast Surgery, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions:Head, Department of Breast Surgery
Checked against a public report (检索 2026-11-15). Positions change; the hospital's website is the final word.
Clinical focus: Diagnosis and standardized treatment of breast cancer, including breast-conserving surgery, oncoplastic techniques, and management of complex breast diseases. Provides counseling and intervention for hereditary breast cancer factors.
Dr. Ou holds a medical doctorate from the University Medical Center Groningen in the Netherlands (2003–2008) and completed postdoctoral training. Graduating from Xinjiang Medical University in 1992, Dr. Ou joined the affiliated cancer hospital. Currently heads the second ward of the Breast Surgery Department. Focuses on evidence-based individualized treatment, sentinel lymph node biopsy, and nipple-sparing mastectomy with immediate reconstruction.
Professional roles
- Standing Committee Member, Tumor Rehabilitation Branch, China Association of Gerontology and Geriatrics
- Standing Committee Member, Breast Disease Professional Committee, Chinese Medical Education Association
- Member, Breast Group, Oncology Branch, Chinese Medical Association
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Ou Jianghua). Papers usually list the name as Jianghua Ou or Ou J.
Selected publications
30 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): The translational chasm in machine learning for triple-negative breast cancer: a quantitative landscape assessment. PubMed 42851301
- Sci Prog, 2026 (senior author): HSPA8 globally modulates transcriptome profile and PI3K/AKT signaling pathway to facilitate malignant progression phenotypes of triple-negative breast cancer. PubMed 42622565
- Cancer Med, 2026 (senior author): Full-Length Transcriptome Profiles Reveal the Molecular Function of Oncogene HNRNPA2B1 in Triple-Negative Breast Cancer. PubMed 42108410
- J Steroid Biochem Mol Biol, 2025 (senior author): Nano-curcumin attenuates tamoxifen resistance and malignant progression in ER-positive breast cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway. PubMed 40617262
- Breast Cancer, 2025 (senior author): Treatment and prognosis of patients with hormone receptor-low positive (1%-10%) breast cancer: a retrospective propensity score-matched analysis. PubMed 40490673
- Biomed Rep, 2025 (senior author): Typical presentation of neurofibromatosis type I in a patient with giant cutaneous neoplasm and café au lait spots: A case report. PubMed 39720298
- Am J Med Sci, 2025 (senior author): FOXO4 suppresses cisplatin resistance of triple-negative breast cancer by inhibiting autophagy. PubMed 39154963
- Sci Rep, 2024 (senior author): Author Correction: KHSRP has oncogenic functions and regulates the expression and alternative splicing of DNA repair genes in breast cancer MDA-MB-231 cells. PubMed 39406855
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion